Holen Sie sich die Stockscreener-App
2.085
9.16%
0.175
Handel nachbörslich:
2.02
-0.065
-3.12%
Schlusskurs vom Vortag:
$1.91
Offen:
$1.97
24-Stunden-Volumen:
943.07K
Relative Volume:
1.30
Marktkapitalisierung:
$55.43M
Einnahmen:
$50,000
Nettoeinkommen (Verlust:
$-41.60M
KGV:
-1.2304
EPS:
-1.6946
Netto-Cashflow:
$-20.20M
1W Leistung:
+19.14%
1M Leistung:
+19.83%
6M Leistung:
+38.08%
1J Leistung:
-25.27%
1-Tages-Spanne:
$1.92
$2.105
1-Wochen-Bereich:
$1.72
$2.105
52-Wochen-Spanne:
$1.09
$2.6091
Inmune Bio Inc Stock (INMB) Company Profile
Firmenname
Inmune Bio Inc
Sektor
Branche
Telefon
(858) 964-3720
Adresse
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
2.085 | 45.99M | 50,000 | -41.60M | -20.20M | -1.6946 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-01 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-07-01 | Herabstufung | Scotiabank | Sector Outperform → Sector Underperform |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-21 | Eingeleitet | Alliance Global Partners | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Outperform |
| 2024-08-22 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-06-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-05-24 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
| 2021-04-21 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-22 | Bestätigt | Maxim Group | Buy |
| 2020-09-01 | Eingeleitet | BTIG Research | Buy |
| 2020-07-15 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Inmune Bio Inc Aktie (INMB) Neueste Nachrichten
INMB|INmune Bio Inc|Price:1.745|Chg%:+0.125 - TradingKey
INmune Bio Inc (INMB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
INmune Bio Inc (INMB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
INmune Bio Inc (INMB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
INmune Bio Inc (INMB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
INMB|INmune Bio Inc|Price:1.620|Chg%:-0.100 - TradingKey
INmune Bio Inc (INMB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
INmune Bio Inc (INMB) Institutional Confidence - TradingKey
INmune Bio Inc (INMB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Inmune Bio stock trades on Nasdaq as investors watch trial progress and cash runway - Ad-hoc-news.de
INMB Achieves Breakthrough in Umbilical Cord Tissue Processing - GuruFocus
INmune Bio And 2 Other Promising Penny Stocks To Consider - webull.com
INmune Bio Achieves Commercial-Ready Manufacturing Milestone for CORDStrom Platform Ahead of Planned Phase 3 Trial - Quiver Quantitative
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform - The Manila Times
INmune Bio's Cord-Tissue Process Supports Planned Phase 3 Trial - Stock Titan
INmune Bio reports press release available - Bitget
INmune Bio Inc (INMB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
INmune Bio publishes preclinical study on brain injury link to Alzheimer’s - Investing.com Nigeria
INmune Bio Study Finds Soluble TNF Inhibition with XPro1595 Prevents TBI-Driven Amyloid Pathology in Alzheimer’s Model - Quiver Quantitative
In mice, XPro1595 prevented amyloid rise after brain injury - Stock Titan
INmune Bio Reports Positive Phase 2 XPro Data - t.co
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer's disease at AAIC - marketscreener.com
Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $8 - Moomoo
INmune Bio reports imaging data from Alzheimer’s drug trial By Investing.com - Investing.com Nigeria
INmune Bio reports imaging data from Alzheimer’s drug trial - Investing.com
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC - The Manila Times
INmune Bio Reports Concordant MRI Biomarker Changes Supporting Early XPro Treatment Activity in Phase 2 Alzheimer’s Study - Quiver Quantitative
INmune Bio says XPro imaging data at AAIC show early Alzheimer’s brain changes - Stock Titan
Form 4 INmune Bio Inc For: 7 July By Investing.com - Investing.com South Africa
Inmune Bio (NASDAQ: INMB) director exercises 14,801 warrants at $1.40 - Stock Titan
INmune Bio (INMB) CSO exercises April 2024 warrants and extends remaining term - Stock Titan
Inmune Bio (INMB) CEO exercises 9,014 April 2024 warrants at $1.40 - Stock Titan
Price to book forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
INmune Bio Inc. (INMB) Edges Higher, Testing Key Resistance Amid Low-Volume TradingIV Spike - dars.gov.et
Enterprise value to revenue forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
Inmune Bio Inc outlines its immunotherapy focus as shares trade on Nasdaq - Ad-hoc-news.de
Earnings Call Summary | INmune Bio(INMB.US) Q4 2025 Earnings Conference - 富途牛牛
Is INmune Bio (NASDAQ:INMB) In A Good Position To Invest In Growth? - Sahm
INmune Bio Inc. Announces Warrant Inducement Offer and Amendment to April 2024 Warrants – Key Details from Latest 8-K Filing – Minichart - Minichart
INmune Bio Executes Warrant Inducement and Extension Agreement - TipRanks
INMB Seeks Patent Approval for CORDStrom Platform - GuruFocus
INmune Bio files U.S. patent for cell therapy platform By Investing.com - Investing.com South Africa
INmune Bio files U.S. patent for cell therapy platform - Investing.com
Inmune Bio Raises ~$0.9M Via $1.40 Warrant Inducement, Extends Remaining Warrants to 2027 - TradingView
INmune Bio (NASDAQ: INMB) cuts warrant price, extends 2027 expiry - Stock Titan
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion - The Manila Times
INmune Bio moves CORDStrom into U.S. patent review - Stock Titan
Price to sales forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
INmune Bio (INMB) Proxy filing Summary - Quartr
Price to earnings forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
Finanzdaten der Inmune Bio Inc-Aktie (INMB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Inmune Bio Inc-Aktie (INMB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lowdell Mark William | Chief Scientific Officer |
Jul 02 '26 |
Option Exercise |
1.40 |
7,211 |
10,095 |
1,518,017 |
| Moss David J | Chief Executive Officer |
Jul 02 '26 |
Option Exercise |
1.40 |
9,014 |
12,620 |
1,294,883 |
1.84%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):